Kaufmann SH - Search Results

1

Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924.

Hou X, Huang F, Carboni JM, Flatten K, Asmann YW, Ten Eyck C, Nakanishi T, Tibodeau JD, Ross DD, Gottardis MM, Erlichman C, Kaufmann SH, Haluska P. Hou X, et al. Among authors: kaufmann sh. Mol Cancer Ther. 2011 Jan;10(1):117-25. doi: 10.1158/1535-7163.MCT-10-0438. Mol Cancer Ther. 2011. PMID: 21220496 Free PMC article.

2

Expression of a 95 kDa membrane protein is associated with low daunorubicin accumulation in leukaemic blast cells.

Doyle LA, Ross DD, Sridhara R, Fojo AT, Kaufmann SH, Lee EJ, Schiffer CA. Doyle LA, et al. Among authors: kaufmann sh. Br J Cancer. 1995 Jan;71(1):52-8. doi: 10.1038/bjc.1995.11. Br J Cancer. 1995. PMID: 7819048 Free PMC article.

3

Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity.

Mullany S, Svingen PA, Kaufmann SH, Erlichman C. Mullany S, et al. Among authors: kaufmann sh. Cancer Chemother Pharmacol. 1998;42(5):391-9. doi: 10.1007/s002800050835. Cancer Chemother Pharmacol. 1998. PMID: 9771954

4

A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity.

Adjei AA, Erlichman C, Davis JN, Cutler DL, Sloan JA, Marks RS, Hanson LJ, Svingen PA, Atherton P, Bishop WR, Kirschmeier P, Kaufmann SH. Adjei AA, et al. Among authors: kaufmann sh. Cancer Res. 2000 Apr 1;60(7):1871-7. Cancer Res. 2000. PMID: 10766174 Clinical Trial.

5

Comparison of potential markers of farnesyltransferase inhibition.

Adjei AA, Davis JN, Erlichman C, Svingen PA, Kaufmann SH. Adjei AA, et al. Among authors: kaufmann sh. Clin Cancer Res. 2000 Jun;6(6):2318-25. Clin Cancer Res. 2000. PMID: 10873082

6

The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.

Erlichman C, Boerner SA, Hallgren CG, Spieker R, Wang XY, James CD, Scheffer GL, Maliepaard M, Ross DD, Bible KC, Kaufmann SH. Erlichman C, et al. Among authors: kaufmann sh. Cancer Res. 2001 Jan 15;61(2):739-48. Cancer Res. 2001. PMID: 11212277

7

Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines.

Adjei AA, Davis JN, Bruzek LM, Erlichman C, Kaufmann SH. Adjei AA, et al. Among authors: kaufmann sh. Clin Cancer Res. 2001 May;7(5):1438-45. Clin Cancer Res. 2001. PMID: 11350915

8

Effect of P-glycoprotein on flavopiridol sensitivity.

Boerner SA, Tourne ME, Kaufmann SH, Bible KC. Boerner SA, et al. Among authors: kaufmann sh. Br J Cancer. 2001 May 18;84(10):1391-6. doi: 10.1054/bjoc.2000.1688. Br J Cancer. 2001. PMID: 11355953 Free PMC article.

9

Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer.

Shridhar V, Bible KC, Staub J, Avula R, Lee YK, Kalli K, Huang H, Hartmann LC, Kaufmann SH, Smith DI. Shridhar V, et al. Among authors: kaufmann sh. Cancer Res. 2001 May 15;61(10):4258-65. Cancer Res. 2001. PMID: 11358853

10

Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks.

Alberts SR, Erlichman C, Sloan J, Okuno SH, Burch PA, Rubin J, Pitot HC, Goldberg RM, Adjei AA, Atherton PJ, Kaufmann SH. Alberts SR, et al. Among authors: kaufmann sh. Ann Oncol. 2001 May;12(5):627-31. doi: 10.1023/a:1011140818150. Ann Oncol. 2001. PMID: 11432620 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,207 results

Search Page

Filters